PCRI's Executive Director, Mark Scholz, MD, explains a clinical trial (NCT03767244) investigating the use of hormone therapy before, during, and after a radical prostatectomy in men with high-risk (Azure) prostate cancer.
0:10 Historically, adjunctive hormone therapy has only been used in men who were being treated with radiation. Also, radical prostatectomy has historically performed poorly in treating high-risk prostate cancer. Recent studies, however, have demonstrated a benefit in men with high-risk prostate cancer who were treated by radical prostatectomy and concurrent hormone therapy.
1:18 Janssen Pharmaceuticals is funding this clinical trial that is investigating 1500 men with high-risk prostate cancer. Half of the study's participants will receive Lupron plus radical prostatectomy and the other half will receive Lupron and Erleada (apalutamide) plus radical prostatectomy.
2:18 The study is designed so that a patient will receive hormone therapy for 6 months, undergo surgery, and then continue on hormone therapy for another 6 months (for a total of 12 months of hormone therapy).
3:17 If the study successfully demonstrates a benefit to using Lupron and Erleada concurrently with radical prostatectomy, then this likely become the standard of treatment for men with high-risk disease who choose radical prostatectomy over radiation.
Don’t know your stage? Take the quiz: Visit www.prostatecan...
To learn more about prostate cancer visit www.pcri.org
To download the free Staging Guide visit pcri.org/prost...
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The information on the Prostate Cancer Research Institute's KZfaq channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.
#ProstateCancer #Prostate #MarkScholzMD